While diagnostic criteria have been established and validated for most neurodegenerative diseases, the considerable overlap between individual nosological entities remains a significant diagnostic challenge. Increasing evidence suggests that neurodegeneration is often initiated by inflammation within the central nervous system. The identification of inflammation could serve as a first signal of the pathophysiological process. As such, validated biological markers ("biomarkers") of neuroinflammation are critically important. This study aimed to assess the presence and levels of inflammatory biomarkers in three neurodegenerative diseases: Lewy body diseases (LBD), multiple system atrophy (MSA), and 4-repeat tauopathies (4RT). A total of 83 LBD, 24 MSA, and 31 4RT patients were included, with 83 control subjects for comparison. Six immune-related proteins were analysed in cerebrospinal fluid (CSF) and blood serum (serum): C3 complement, C4 complement, haptoglobin, transferrin, orosomucoid, and β2 microglobulin (β2M). ANCOVA statistical analysis revealed significantly lower levels of several inflammatory biomarkers in LBD (CSF: transferrin, C3 complement, orosomucoid; Serum: orosomucoid, β2M) and MSA (CSF: transferrin, C3 complement, C4 complement, orosomucoid) compared to controls. Significant differences were also observed between the synucleinopathy patient groups (LBD and MSA) and 4RT in serum levels of C3 complement. Additionally, the CSF/serum quotients for transferrin (LBD and MSA) and C3 complement (LBD) were significantly lower in disease relative to controls. These findings suggest that inflammatory processes may play a role in the pathophysiology of neurodegenerative proteinopathies, warranting further research to confirm these associations. The identification of potential fluid biomarkers would then represent a promising step forward in the field.

Department of Clinical Biochemistry University Hospital Olomouc Olomouc Czech Republic

Department of Immunology Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

Department of Immunology University Hospital Olomouc Olomouc Czech Republic

Department of Medical Biophysics Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

Department of Neurology Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

Department of Neurology University Hospital Olomouc Olomouc Czech Republic

Laboratory for Inherited Metabolic Disorders Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

Zobrazit více v PubMed

Adamu A, Li S, Gao F, Xue G (2024) ‘The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets’. Front Aging Neurosci, 16

Al-Bachari S, Naish J, Parker G, Emsley H, Parkes L (2020) ‘Blood-Brain Barrier Leakage Is Increased in Parkinson’s Disease’. Front Physiol, 11

Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB (2014) Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 85(8):923–927 DOI

Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Troster AI, Vidailhet M, Weiner WJ (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80(5):496–503 PubMed DOI PMC

Asano T, Ito H, Kariya Y, Hoshi K, Yoshihara A, Ugawa Y, Sekine H, Hirohata S, Yamaguchi Y, Sato S, Kobayashi H, Migita K, Ohira H, Hashimoto Y, Watanabe H (2017) Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus. Plos one 12(10):18 DOI

Ayton S, Lei P, McLean C, Bush AI, Finkelstein DI (2016) Transferrin protects against parkinsonian neurotoxicity and is deficient in Parkinson’s substantia Nigra. Signal Transduct Target Therapy 1:6

Balistreri CR, Monastero R (2023) ‘Neuroinflammation and Neurodegenerative Diseases: How Much Do We Still Not Know?‘. Brain Sci, 14(1)

Bamm VV, Geist AM, Harauz G (2017) Correlation of geographic distributions of haptoglobin alleles with prevalence of multiple sclerosis (MS) - a narrative literature review. Metab Brain Dis 32(1):19–34 PubMed DOI

Bhidayasiri R, Rattanachaisit W, Phokaewvarangkul O, Lim TT, Fernandez HH (2019) Exploring bedside clinical features of parkinsonism: A focus on differential diagnosis. Parkinsonism Relat Disord 59:74–81 PubMed DOI

Bourel J, Planche V, Dubourdieu N, Oliveira A, Sere A, Ducourneau E, Tible M, Maitre M, Leste-Lasserre T, Nadjar A, Desmedt A, Ciofi P, Oliet S, Panatier A, Tourdias T (2021) ‘Complement C3 mediates early hippocampal neurodegeneration and memory impairment in experimental multiple sclerosis’. Neurobiol Dis, 160

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Hoglinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16(7):552–563 PubMed DOI PMC

Ceciliani F, Lecchi C (2019) The immune functions of alpha(1) acid glycoprotein. Curr Protein Pept Sci 20(6):505–524 PubMed DOI

Chaubey K, Rao M, Alam S, Waghmare C, Bhattacharya B (2016) Increased expression of immune modulator proteins and decreased expression of Apolipoprotein A-1 and haptoglobin in blood plasma of sarin exposed rats. Chemico-Biol Interact 246:36–44 DOI

Chertkow H, Borrie M, Whitehead V, Black S, Feldman H, Gauthier S, Hogan D, Masellis M, McGilton K, Rockwood K, Tierney M, Andrew M, Hsiung G, Camicioli R, Smith E, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips N, MacNamara E, Dixon R, Duchesne S, MacKenzie I, Rylett R (2019) The comprehensive assessment of neurodegeneration and dementia: Canadian cohort study, vol 46. Canadian journal of neurological sciences, pp 499–511

Chi X, Yin S, Sun Y, Kou L, Zou W, Wang Y, Jin Z, Wang T, Xia Y (2025) Astrocyte-neuron communication through the complement C3-C3aR pathway in Parkinson’s disease. BRAIN Behav Immun 123:229–243 PubMed DOI

Chiu SY, Wyman-Chick KA, Ferman TJ, Bayram E, Holden SK, Choudhury P, Armstrong MJ (2023) Sex differences in dementia with lewy bodies: focused review of available evidence and future directions. Parkinsonism Relat Disord 107:11 DOI

Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, Savulich G, Prats-Sedano MA, Heslegrave AJ, Zetterberg H, Su L, Rowe JB, O’Brien JT (2022) ‘Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy’. J Neurol Neurosurg Psychiatry, pp. 8

Cocciolo A, Di Domenico F, Coccia R, Fiorini A, Cai J, Pierce WM, Mecocci P, Butterfield DA, Perluigi M (2012) Decreased expression and increased oxidation of plasma haptoglobin in alzheimer disease: insights from redox proteomics. Free Radic Biol Med 53(10):1868–1876 PubMed DOI

Costa-Mallen P, Checkoway H, Zabeti A, Edenfield MJ, Swanson PD, Longstreth WT, Franklin GM, Smith-Weller T, Sadrzadehl SMH (2008) The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson’s disease. Am J Med Genet Part B-Neuropsychiatric Genet 147B(2):216–222 DOI

Costa-Mallen P, Zabetian CP, Hu SC, Agarwal P, Yearout D, Checkoway H (2016) Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease. J Neural Transm 123(11):1319–1330 PubMed DOI

Dignass A, Farrag K, Stein J (2018) Limitations of serum ferritin in diagnosing Iron deficiency in inflammatory conditions. Int J Chronic Dis 2018:pp9394060

Dufek M, Hamanova M, Lokaj J, Goldemund D, Rektorova I, Michalkova Z, Sheardova K, Rektor I (2009) Serum inflammatory biomarkers in Parkinson’s disease. Parkinsonism Relat Disord 15(4):318–320 PubMed DOI

Elpek GO (2021) Orosomucoid in liver diseases. World J Gastroenterol 27(45):7739–7747 PubMed DOI PMC

Garland P, Morton MJ, Haskins W, Zolnourian A, Durnford A, Gaastra B, Toombs J, Heslegrave AJ, More J, Okemefuna AI, Teeling JL, Graversen JH, Zetterberg H, Moestrup SK, Bulters DO, Galea I (2020) Haemoglobin causes neuronal damage in vivo which is preventable by haptoglobin. Brain Commun 2(1):17 DOI

Gille G, Reichmann H (2011) Iron-dependent functions of mitochondria–relation to neurodegeneration. J Neural Transm (Vienna) 118(3):349–359 PubMed DOI

Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–676 PubMed DOI PMC

Giri P, Banerjee A, Ghosal A, Layek B (2024) ‘Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications’. Int J Mol Sci, 25

Gregersen E, Betzer C, Kim WS, Kovacs G, Reimer L, Halliday GM, Thiel S, Jensen PH (2021) Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. J Neuroinflamm 18(1):10 DOI

Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O (2018) Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders. Sci Rep 8:9 DOI

Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Muller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI (2017) Litvan, I. and movement disorder Soc-Endorsed, P. Mov Disord 32(6):853–864 ‘Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria’ PubMed PMC

Hourfar H, Aliakbari F, Aqdam S, Nayeri Z, Bardania H, Otzen D, Morshedi D (2023) The impact of α-synuclein aggregates on blood-brain barrier integrity in the presence of neurovascular unit cells. Int J Biol Macromol 229:305–320 PubMed DOI

Jo M, Kim JH, Song GJ, Seo M, Hwang EM, Suk K (2017) Astrocytic Orosomucoid-2 modulates microglial activation and neuroinflammation. J Neurosci 37(11):2878–2894 PubMed DOI PMC

Kaleta M, Hényková E, Mensíková K, Friedecky D, Kvasnicka A, Klícová K, Konícková D, Strnad M, Kanovsky P, Novák O (2024) Patients with neurodegenerative proteinopathies exhibit altered Tryptophan metabolism in the serum and cerebrospinal fluid. ACS Chem Neurosci 15:582–592 PubMed DOI

Kawabata H (2019) Transferrin and transferrin receptors update. Free Radic Biol Med 133:46–54 PubMed DOI

Konicková D, Mensíková K, Klícová K, Chudácková M, Kaiserová M, Prikrylová H, Otruba P, Nevrly M, Hlustík P, Hényková E, Kaleta M, Friedecky D, Matej R, Strnad M, Novák O, Plihalová L, Rosales R, Colosimo C, Kanovsky P (2023) Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross-correlation study. J Neurochem 167:168–182 PubMed DOI

Konícková D, Mensíková K, Tucková L, Hényková E, Strnad M, Friedecky D, Stejskal D, Matej R, Kanovsky P (2022) ‘Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status’, Biomedicines, 10(7)

Kwon H, Koh S (2020) ‘Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes’. TRANSLATIONAL NEURODEGENERATION, 9

Loeffler DA, Camp DM, Conant SB (2006) Complement activation in the Parkinson’s disease substantia Nigra: an immunocytochemical study. J Neuroinflamm 3:8 DOI

Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, LoIacono N, Cote L, Mayeux R (1997) Altered systemic iron metabolism in Parkinson’s disease. Neurology 49(3):714–717 PubMed DOI

Majerova P, Michalicova A, Cente M, Hanes J, Vegh J, Kittel A, Kosikova N, Cigankova V, Mihaljevic S, Jadhav S, Kovac A (2019) ‘Trafficking of immune cells across the blood-brain barrier is modulated by neurofibrillary pathology in tauopathies’, Plos one, 14(5)

McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, Kantarci K, Muscio C, O’Brien JT, Postuma RB, Aarsland D, Ballard C, Bonanni L, Donaghy P, Emre M, Galvin JE, Galasko D, Goldman JG, Gomperts SN, Honig LS, Ikeda M, Leverenz JB, Lewis SJG, Marder KS, Masellis M, Salmon DP, Taylor JP, Tsuang DW, Walker Z, Tiraboschi P, Prodromal DL B. D. S. G. (2020) ‘Research criteria for the diagnosis of prodromal dementia with Lewy bodies’. Neurology, 94(17), pp. 743–755

Mishra M, Rawji K, Keough M, Kappen J, Dowlatabadi R, Vogel H, Chopra S, Distéfano-Gagné F, Dufour A, Gosselin D, Yong V (2021) Harnessing the benefits of neuroinflammation: generation of macrophages/microglia with prominent remyelinating properties. J Neurosci 41:3366–3385 PubMed DOI PMC

Mogi M, Harada M, Kojima K, Adachi T, Narabayashi H, Fujita K, Naoi M, Nagatsu T (1989) Beta 2-microglobulin decrease in cerebrospinal fluid from parkinsonian patients. Neurosci Lett 104(1–2):241–246 PubMed DOI

Naryzny SN, Legina OK (2021) Haptoglobin as a biomarker. Biochem Moscow-Supplement Ser B-Biomedical Chem 15(3):184–198 DOI

Pfeiffer CM, Looker AC (2017) Laboratory methodologies for indicators of iron status: strengths, limitations, and analytical challenges. Am J Clin Nutr 106(6):1606S–1614S PubMed DOI PMC

Philbert S, Xu J, Unwin R, Dowsey A, Cooper G (2021) Widespread severe cerebral elevations of haptoglobin and haemopexin in sporadic Alzheimer’s disease: Evidence for a pervasive microvasculopathy. Biochemical and biophysical research communications, p 555

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1599 PubMed DOI

Qu Y, Li J, Qin Q, Wang D, Zhao J, An K, Mao Z, Min Z, Xiong Y, Xue Z (2023) A systematic review and meta-analysis of inflammatory biomarkers in Parkinson’s disease. NPJ Parkinsons Dis 9(1):18 PubMed DOI PMC

Qun S, Hu FY, Wang GP, Wu JC, Tang QQ, Zhang J, Chen ZX, Wang XQ, Liu QW, Ge W (2019) Serum beta2-microglobulin levels are highly associated with the risk of acute ischemic stroke. Sci Rep 9:8 DOI

Rani K, Pal A, Gurnani B, Agarwala P, Sasmal D, Jain N (2023) ‘An Innate Host Defense Protein b2-Microglobulin Keeps a Check on a-Synuclein amyloid Assembly: Implications in Parkinson’s Disease’. J Mol Biol, 435

Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23(1):55–63 PubMed DOI

Sabbir M (2024) ‘Loss of calcium/calmodulin-dependent protein kinase kinase 2, transferrin, and transferrin receptor proteins in the temporal cortex of Alzheimer’s patients postmortem is associated with abnormal iron homeostasis: implications for patient survival’. Front Cell dev biology, 12

Saeed U, Compagnone J, Aviv RI, Strafella AP, Black SE, Lang AE, Masellis M (2017) ‘Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts’, Translational neurodegeneration, 6, p. 25

Santaella A, Kuiperij HB, van Rumund A, Esselink RAJ, van Gool AJ, Bloem BR, Verbeek MM (2020) Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms. BMC Neurol 20(1):8 DOI

Sheng Z, Wang L, Chen M, Zhong F, Wu S, Liang S, Song J, Chen L, Chen Y, Chen S, Yu W, Lue Y (2025) ‘Cerebrospinal fluid β2-microglobulin promotes the tau pathology through microglia-astrocyte communication in Alzheimer’s disease’. Alzheimers Res Therapy, 17(1)

Song SK, Lee SK, Lee JJ, Lee JE, Choi HS, Sohn YH, Lee PH (2011) Blood-brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy. Neurobiol Aging 32(12):2183–2189 PubMed DOI

Starhof C, Winge K, Heegaard NHH, Skogstrand K, Friis S, Hejl A (2018) Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes. J Neuroinflamm 15:7 DOI

Surendranathan A, Rowe JB, O’Brien JT (2015) Neuroinflammation in lewy body dementia. Parkinsonism Relat Disord 21(12):1398–1406 PubMed DOI

Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V (2022) Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol 22(11):657–673 PubMed DOI PMC

Thurman JM, Yapa R (2019) Complement therapeutics in autoimmune disease. Front Immunol 10:9 DOI

Tokutake T, Kasuga K, Tsukie T, Ishiguro T, Shimohata T, Onodera O, Ikeuchi T (2022) Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy. Parkinsonism Relat Disord 102:30–35 PubMed DOI

Villar-Conde S, Astillero-Lopez V, Gonzalez-Rodriguez M, Saiz-Sanchez D, Martinez-Marcos A, Ubeda-Banon I, Flores-Cuadrado A (2023) ‘Synaptic Involvement of the Human Amygdala in Parkinson’s Disease’, Molecular & cellular proteomics, 22(12)

Vranová H, Hényková E, Kaiserová M, Mensíková K, Vastík M, Mares J, Hlustík P, Zapletalová J, Strnad M, Stejskal D, Kanovsky P (2014) Tau protein, beta-amyloid PubMed DOI

Vranová H, Hényková E, Mares J, Kaiserová M, Mensíková K, Vastík M, Hlustík P, Zapletalová J, Strnad M, Stejskal D, Kanovsky P (2016) Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. J Neurol Sci 361:117–121 DOI

Wang YP, Kinzie E, Berger FG, Lim SK, Baumann H (2001) Haptoglobin, an inflammation-inducible plasma protein. Redox Rep 6(6):379–385 PubMed DOI

Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, Zhang J (2011) Complement 3 and factor H in human cerebrospinal fluid in Parkinson’s disease, Alzheimer’s disease, and Multiple-System atrophy. Am J Pathol 178(4):1509–1516 PubMed DOI PMC

Wang HL, Liu YM, Zhao JY, Guo X, Hu M, Chen YZ (2021) Possible inflammatory mechanisms and predictors of Parkinson’s disease patients with fatigue (Brief Review). Clin Neurol Neurosurg 208:7 DOI

Wu T, Dejanovic B, Gandham V, Gogineni A, Edmonds R, Schauer S, Srinivasan K, Huntley M, Wang Y, Wang T, Hedehus M, Barck K, Stark M, Ngu H, Foreman O, Meilandt W, Elstrott J, Chang M, Hansen D, Carano R, Sheng M, Hanson J (2019) Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. CELL Rep 28(8):2111– PubMed DOI

Xu W, Zhi Y, Yuan YS, Zhang BF, Shen YT, Zhang H, Zhang KZ, Xu Y (2018) Correlations between abnormal iron metabolism and non-motor symptoms in Parkinson’s disease. J Neural Transm 125(7):1027–1032 PubMed DOI

Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinsons-disease are recognized by antibodies to complement proteins. Acta Neuropathol 84(1):100–104 PubMed DOI

Yekani M, Memar M (2023) ‘Immunologic biomarkers for bacterial meningitis’. Clin Chim Acta, 548

Yerbury JJ, Rybchyn MS, Easterbrook-Smith SB, Henriques C, Wilson MR (2005) The acute phase protein haptoglobin is a mammalian extracellular chaperone with an action similar to clusterin. Biochemistry 44(32):10914–10925 PubMed DOI

Zeman D, Adam P, Kalistova H, Sobek O, Kelbich P, Andel J, Andel M (2000) Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients. Acta Neurol Scand 101(2):89–94 PubMed DOI

Zhang WF, Xiao D, Mao QW, Xia HB (2023) Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Therapy 8(1):32

Zhao XR, Song S, Sun GH, Strong R, Zhang J, Grotta JC, Aronowski J (2009) Neuroprotective role of haptoglobin after intracerebral hemorrhage. J Neurosci 29(50):15819–15827 PubMed DOI PMC

Zhao Y, Zheng Q, Hong Y, Gao Y, Hu J, Lang M, Zhang H, Zhou Y, Luo H, Zhang X, Sun H, Yan X, Huang T, Wang Y, Xu H, Liu C, Wang X (2023) β PubMed DOI